

Listing of Claims

1-20. (Canceled)

21. (Currently Amended) A method of eliminating cancerous prostate epithelial cells comprising: providing an antibody ~~bound~~ coupled to a cytotoxic agent which antibody binds to an outer membrane domain of prostate specific membrane antigen having the sequence set forth in SEQ ID NO:128 and contacting said cells with the antibody ~~bound~~ coupled to the cytotoxic agent under conditions effective to permit both binding of the antibody to the outer membrane domain of the prostate specific membrane antigen and eliminating said cells.

22. (Canceled).

23. (Currently Amended) A method according to claim 21, wherein said contacting is carried out in a living mammal and comprises: administering the antibody ~~bound~~ coupled to the cytotoxic agent to the mammal under conditions effective to permit both binding of the antibody ~~bound~~ coupled to the cytotoxic agent to the outer membrane domain of the prostate specific membrane antigen and eliminating of said cells.

24. (Previously presented) A method according to claim 23, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or intramuscularly.

25. (Currently Amended) A method according to claim 21, wherein the antibody ~~bound~~ coupled to the cytotoxic

agent is a monoclonal antibody or a polyclonal antibody.

26. (Canceled).

27. (Currently Amended) A method according to claim 21, wherein the cytotoxic agent ~~bound~~ coupled to the antibody is effective to eliminate said cells upon binding of the antibody to the outer membrane domain of the prostate specific membrane antigen of said cells.

28. (Canceled).

29. (Previously Presented) A method according to claim 21, wherein the cytotoxic agent is a drug, a toxin, a radioactive substance, a chemotherapeutic, an enzyme or a molecule of fungal, viral or bacterial origin.

30. (Currently Amended) A method according to claim 21, wherein the antibody ~~bound~~ coupled to the cytotoxic agent is in a composition further comprising a physiologically acceptable carrier, diluent, or stabilizer.

31. (Currently Amended) A method according to claim 21, wherein the antibody ~~bound~~ coupled to the cytotoxic agent is in a composition further comprising a pharmaceutically acceptable carrier, diluent, or stabilizer.

32 to 58. (Canceled)